Showing 4581-4590 of 7766 results for "".
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older
- Psoriasis Therapy Linked to Reduced Coronary Inflammationhttps://practicaldermatology.com/news/psoriasis-therapy-linked-to-reduced-coronary-inflammation/2460112/Anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat a
- Summer AAD News: Dramatic Spike in Female Skin Cancer Linked to Tanninghttps://practicaldermatology.com/news/summer-aad-news-dramatic-spike-in-female-skin-cancer-linked-to-tanning/2460105/Skin cancer in women is on the rise, and indoor tanning may be to blame, according to new research presented at the 2019 American Academy of Dermatology Summer Meeting in New York City. Between 1970 and 2009, rates of melanoma increased 800 percent among women ages 18-39, making it the
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 S
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- Second US Patent Issued to Alastin Based On TriHex Technologyhttps://practicaldermatology.com/news/second-us-patent-issued-to-alastin-based-on-trihex-technology/2460092/Alastin Skincare, Inc. was issued a second U.S. Patent, No. 10,286,030 from the United States Patent and Trademark Office covering Alastin's platform TriHex Technology. The patent also covers a variety of topical compositions based on Alastin's TriHex Technology. The coma
- Topical Collagen Powder May Be Effective for Wound Closurehttps://practicaldermatology.com/news/collagen-may-be-effective-for-wound-closure/2460091/Collagen powder is as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study published in the Journal of Drugs in Dermatology. Researchers investigated the efficacy of topical collagen powder compared
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin
- Positive Top-Line Results Seen in Study of Crisaborole for Mild to Moderate AD in Young Childrenhttps://practicaldermatology.com/news/positive-top-line-results-seen-in-study-of-crisaborole-of-for-mild-to-moderate-ad-in-young-children/2460085/Pfizer’s crisaborole ointment (Eucrisa) was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), according to top-line results from a Phase 4 study (CrisADe CARE 1). The data from the trial are supportive of the primary stud
- Meet truSculpt flex: Cutera’s Solution for Toned Abs, Butts and Thighshttps://practicaldermatology.com/news/meet-trusculpt-flex-cuteras-solution-for-toned-abs-butts-and-thighs/2460084/Cutera is launching the new truSculpt flex, muscle sculpting platform in the United States, and commercial shipments are slated to begin immediately. truSculpt flex is FDA-cleared for the indications of the improvement of abdominal tone, strengt